Opaleye Management’s iBio IBIO Stock Holding History

Opaleye Management’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-375,000	Closed	-$310K	–	57
2025 Q3	$310K	Hold	375,000	–	–	0.04%	42
2025 Q2	$285K	Hold	375,000	–	–	0.06%	39
2025 Q1	$1.51M	Hold	375,000	–	–	0.34%	37
2024 Q4	$919K	Hold	375,000	–	–	0.16%	33
2024 Q3	$833K	Hold	375,000	–	–	0.14%	43
2024 Q2	$791K	Sell	375,000 -305,000	-45%	-$656K	0.18%	45
2024 Q1	$2.76M	Buy	+680,000	New	+$855K	0.6%	39

Other funds holding IBIO

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Opaleye Management's IBIO Position: Q4 2025 in Review

Opaleye Management sold out of iBio (IBIO) in Q4 2025, closing a stake of 375,000 shares — an estimated $310K sold.

Opaleye Management first reported a position in IBIO in Q1 2024 and held it in 7 quarters. The position peaked at $2.76M in Q1 2024. 50 funds tracked by Wall St. Rank hold IBIO as of Q4 2025.

Opaleye Management reported no remaining iBio position as of Q4 2025 after selling out during the quarter.
Opaleye Management sold 375,000 iBio shares in Q4 2025, an estimated $310K.
Opaleye Management first reported a position in iBio in Q1 2024 and held it in 7 quarters.
Opaleye Management's iBio position peaked at $2.76M in Q1 2024.
50 funds tracked by Wall St. Rank held iBio as of Q4 2025.

Based on Opaleye Management's 13F filing for Q4 2025, filed 17 Feb 2026.